EE200200522A - Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina - Google Patents
Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase raviminaInfo
- Publication number
- EE200200522A EE200200522A EEP200200522A EEP200200522A EE200200522A EE 200200522 A EE200200522 A EE 200200522A EE P200200522 A EEP200200522 A EE P200200522A EE P200200522 A EEP200200522 A EE P200200522A EE 200200522 A EE200200522 A EE 200200522A
- Authority
- EE
- Estonia
- Prior art keywords
- enzyme
- pharmaceutical composition
- active ingredient
- composition containing
- antitumor drug
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18938700P | 2000-03-15 | 2000-03-15 | |
| PCT/US2001/008589 WO2001068145A2 (en) | 2000-03-15 | 2001-03-15 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200522A true EE200200522A (et) | 2004-04-15 |
Family
ID=22697116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200522A EE200200522A (et) | 2000-03-15 | 2001-03-15 | Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6844318B2 (et) |
| EP (1) | EP1263473A2 (et) |
| JP (1) | JP2003526683A (et) |
| KR (1) | KR20030009388A (et) |
| CN (1) | CN1418112A (et) |
| AU (2) | AU2001245836A1 (et) |
| BR (1) | BR0109266A (et) |
| CA (1) | CA2401873A1 (et) |
| CZ (1) | CZ20022998A3 (et) |
| EE (1) | EE200200522A (et) |
| HU (1) | HUP0300590A2 (et) |
| IL (1) | IL151400A0 (et) |
| MX (1) | MXPA02009019A (et) |
| NO (1) | NO20024238D0 (et) |
| PL (1) | PL360826A1 (et) |
| RU (1) | RU2002127425A (et) |
| SK (1) | SK12872002A3 (et) |
| TR (1) | TR200202183T2 (et) |
| WO (1) | WO2001068145A2 (et) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6685301A (en) * | 2000-06-14 | 2001-12-24 | Corixa Corp | Prodrug compounds with isoleucine |
| CA2447023A1 (en) * | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| JP4541693B2 (ja) * | 2001-06-11 | 2010-09-08 | メダレックス，インコーポレイティド | Ｃｄ１０活性化プロドラッグ化合物 |
| WO2003051393A2 (en) * | 2001-12-17 | 2003-06-26 | University Of Wales College Of Medicine | Enzymatic cleavable reagents for specific delivery to disease sites |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| JP4511805B2 (ja) * | 2002-04-26 | 2010-07-28 | 武田薬品工業株式会社 | ネプリライシンの活性測定法 |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| FR2851471B1 (fr) * | 2003-02-24 | 2006-07-28 | Synt Em | Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison |
| DE10310082A1 (de) * | 2003-03-07 | 2004-09-16 | Ktb Tumorforschungsgesellschaft Mbh | Protein-bindende Doxorubicin-Peptid-Derivate |
| US20100113328A1 (en) * | 2003-05-29 | 2010-05-06 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
| JP4654418B2 (ja) | 2004-03-31 | 2011-03-23 | 独立行政法人産業技術総合研究所 | 上皮系細胞増殖促進剤 |
| JP2007099750A (ja) * | 2005-02-25 | 2007-04-19 | Hokkaido Univ | 腫瘍組織で選択的に分解性を示す血中滞留性素子 |
| WO2006124711A1 (en) * | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
| JP2010501026A (ja) * | 2006-06-30 | 2010-01-14 | インターフェース バイオロジクス，インコーポレーテッド | 生体応答性ポリマー |
| EP1977765A1 (en) * | 2007-04-03 | 2008-10-08 | Diatos | Peptide prodrugs |
| GB0707034D0 (en) * | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| ITUD20130024A1 (it) | 2013-02-22 | 2014-08-23 | Carlo Galli | Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo |
| WO2014145242A1 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The University Of Illinois | Peptide-coated polymer carriers |
| GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
| EP3038645B1 (en) * | 2013-08-26 | 2019-01-30 | Health Research, Inc. | Method for treatment of erbb2 positive cancers |
| CN107075490A (zh) | 2014-08-20 | 2017-08-18 | 健康研究公司 | 用于预防和/或治疗erbb1阳性癌症的方法 |
| EP2995612A1 (en) * | 2014-09-12 | 2016-03-16 | Université de Strasbourg | Novel non-natural amino acids, their process of preparation and uses thereof |
| CA3073806A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
| PH12022550039A1 (en) | 2019-07-10 | 2023-06-26 | Cybrexa 3 Inc | Peptide conjugates of cytotoxins as therapeutics |
| CA3202532A1 (en) | 2020-12-21 | 2022-06-30 | Shek Hang Benedict LAW | Peptide-linked drug delivery system |
| CA3203072A1 (en) | 2020-12-22 | 2022-06-30 | Andrea CASAZZA | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
| CN113876968B (zh) * | 2021-10-29 | 2023-06-09 | 上海市第一人民医院 | Mmp9响应的t1/t2切换型mr纳米探针及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4466919A (en) | 1982-12-16 | 1984-08-21 | Monsanto Company | Peptide substrates for mammalian collagenase |
| FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
| US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5618528A (en) * | 1994-02-28 | 1997-04-08 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
| US5866679A (en) | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| US6143864A (en) | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
| US5962216A (en) | 1994-08-19 | 1999-10-05 | La Region Wallonne | Tumor-activated prodrug compounds and treatment |
| JP2000506494A (ja) | 1995-10-18 | 2000-05-30 | メルク エンド カンパニー インコーポレーテッド | 良性前立腺過形成の治療に有用な複合体 |
| WO1997048725A1 (en) | 1996-06-21 | 1997-12-24 | Peptech Limited | Novel peptides for prevention and treatment of infection |
| AU4412297A (en) | 1996-09-10 | 1998-04-02 | Burnham Institute, The | Tumor homing molecules, conjugates derived therefrom, and methods of using sa me |
| EP0926955A4 (en) | 1996-09-12 | 2003-05-07 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer |
| EP0964690B1 (en) | 1996-10-15 | 2003-07-09 | The Liposome Company, Inc. | Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| HRP970566A2 (en) | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
| EP1005357A1 (en) | 1997-04-14 | 2000-06-07 | The Regents Of The University Of California | Peptide antiestrogen compositions and methods for treating breast cancer |
| CA2295860A1 (en) * | 1997-07-10 | 1999-01-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| AU773420B2 (en) | 1998-12-11 | 2004-05-27 | Medarex, Inc. | Prodrug compounds and process for preparation thereof |
| WO2000059930A1 (en) | 1999-04-05 | 2000-10-12 | Merck & Co., Inc. | A method of treating cancer |
| CA2369999A1 (en) | 1999-04-28 | 2000-11-02 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| WO2000069472A2 (en) * | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
-
2001
- 2001-03-15 KR KR1020027012124A patent/KR20030009388A/ko not_active Withdrawn
- 2001-03-15 CZ CZ20022998A patent/CZ20022998A3/cs unknown
- 2001-03-15 CA CA002401873A patent/CA2401873A1/en not_active Abandoned
- 2001-03-15 TR TR2002/02183T patent/TR200202183T2/xx unknown
- 2001-03-15 AU AU2001245836A patent/AU2001245836A1/en not_active Abandoned
- 2001-03-15 AU AU4583601A patent/AU4583601A/xx active Pending
- 2001-03-15 WO PCT/US2001/008589 patent/WO2001068145A2/en not_active Ceased
- 2001-03-15 EE EEP200200522A patent/EE200200522A/et unknown
- 2001-03-15 EP EP01918798A patent/EP1263473A2/en not_active Withdrawn
- 2001-03-15 RU RU2002127425/15A patent/RU2002127425A/ru unknown
- 2001-03-15 PL PL36082601A patent/PL360826A1/xx not_active Application Discontinuation
- 2001-03-15 HU HU0300590A patent/HUP0300590A2/hu unknown
- 2001-03-15 IL IL15140001A patent/IL151400A0/xx unknown
- 2001-03-15 BR BR0109266-9A patent/BR0109266A/pt not_active Application Discontinuation
- 2001-03-15 JP JP2001566708A patent/JP2003526683A/ja active Pending
- 2001-03-15 CN CN01806549A patent/CN1418112A/zh active Pending
- 2001-03-15 US US09/808,832 patent/US6844318B2/en not_active Expired - Lifetime
- 2001-03-15 MX MXPA02009019A patent/MXPA02009019A/es unknown
- 2001-03-15 SK SK1287-2002A patent/SK12872002A3/sk unknown
-
2002
- 2002-09-05 NO NO20024238A patent/NO20024238D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003526683A (ja) | 2003-09-09 |
| RU2002127425A (ru) | 2004-03-27 |
| US20020103133A1 (en) | 2002-08-01 |
| BR0109266A (pt) | 2003-04-29 |
| CN1418112A (zh) | 2003-05-14 |
| NO20024238D0 (no) | 2002-09-05 |
| HUP0300590A2 (hu) | 2003-07-28 |
| AU2001245836A1 (en) | 2002-07-16 |
| WO2001068145A3 (en) | 2002-07-11 |
| IL151400A0 (en) | 2003-04-10 |
| CZ20022998A3 (cs) | 2003-05-14 |
| PL360826A1 (en) | 2004-09-20 |
| CA2401873A1 (en) | 2001-09-20 |
| US6844318B2 (en) | 2005-01-18 |
| AU4583601A (en) | 2001-09-24 |
| SK12872002A3 (sk) | 2003-05-02 |
| EP1263473A2 (en) | 2002-12-11 |
| MXPA02009019A (es) | 2003-02-12 |
| TR200202183T2 (tr) | 2007-01-22 |
| KR20030009388A (ko) | 2003-01-29 |
| WO2001068145A2 (en) | 2001-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200522A (et) | Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina | |
| DZ3227A1 (fr) | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees | |
| IL163552A (en) | Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same | |
| ITTO20010005A1 (it) | Formulazione farmaceutica. | |
| NO20022970L (no) | Hydrogel-drevet medikamentdoseringsform | |
| BR0115810B1 (pt) | composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos. | |
| NO20030627L (no) | Hydrogel-drevet medikament doseringsform | |
| EE05129B1 (et) | Konjugeeritud strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend | |
| IL161940A0 (en) | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | |
| DK1208864T4 (da) | Forbedringer til lægemiddelafgivelsesindretninger | |
| ITMI20001173A0 (it) | Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva. | |
| EE200300240A (et) | Arüülitud furaan- ja tiofeenkarboksamiid, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks | |
| IL163866A0 (en) | 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient | |
| HUP0303653A3 (en) | Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient | |
| IL164699A0 (en) | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | |
| ATE354362T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
| DE69923336D1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
| ZA200308221B (en) | Pharmaceutical compositions for oral and topical administration. | |
| DK1225902T3 (da) | Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden | |
| HUP0303673A3 (en) | Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient | |
| AU2001277738A1 (en) | Piperidine derivatives and drugs containing these derivatives as the active ingredient | |
| HUP0201696A3 (en) | Cyclic peptides, pharmaceutical compositions comprising thereof and their use | |
| AU2001260089A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
| AR025867A1 (es) | Formulacion portasdora farmaceutica | |
| EE200200480A (et) | Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon |